Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581843 | 0.88 | PRMT5 (0.42) | TSHRHTTATMNPC1ALDH1A1 | |
| SCHEMBL4582647 | 0.77 | NPC1 (0.46) | HTTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL29300518 | 0.77 | L3MBTL1 (0.53) | TSHRATMNPC1ALDH1A1MEN1 | |
| SCHEMBL23261788 | 0.77 | NAMPT (0.50) | TSHRHTTATMNPC1ALDH1A1 | |
| SCHEMBL29299663 | 0.76 | FOLH1 (0.53) | TSHRHTTATMNPC1ALDH1A1 | |
| SCHEMBL29300447 | 0.76 | L3MBTL1 (0.55) | ATMNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL18843660 | 0.74 | ALDH1A1 (0.68) | TSHRATMNPC1ALDH1A1MEN1 | |
| SCHEMBL18843662 | 0.74 | ALDH1A1 (0.68) | TSHRATMNPC1ALDH1A1MEN1 | |
| SCHEMBL14192211 | 0.74 | ALDH1A1 (0.72) | HTTATMNPC1ALDH1A1MEN1 | |
| SCHEMBL15499796 | 0.73 | NPC1 (0.56) | HTTATMNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO SUISSE SA (CH) | 2003-09-11 | — | — | US | claimed |
| US-7351389-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2008-04-01 | — | — | US | disclosed |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| US-6875864-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-05 | — | — | US | disclosed |
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO SUISSE SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-0543482-B1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INT BV (NL) | 2002-02-06 | — | — | EP | disclosed |
| EP-0543482-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | ARGLU1, PRMT1, AADAC | TSHR 2437/4885HTT 3097/4885ATM 2468/4885 |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | AADAC, ANXA3, AAAS | TSHR 2139/4885HTT 2496/4885ATM 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.